Investors
Breaking News:
Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis
https://abivax.gcs-web.com/news-releases/news-release-details/abivax-completes-induction-treatment-last-patient-abx464-phase
Share Profile
Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.
- ISIN code: FR0012333284
- Symbol: ABVX
- ICB Classification: Healthcare 4000/ Biotechnology 4573
- Market: Euronext Paris-Compartment B
- Type of Listing: continuous
- Number of shares: 14,394,243 as of January 31, 2021
- Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
- Eligible to French PEA PME
Analysts
LifeSci Capital Alpha Series:
Adam Evertts & David ShermanBryan, Garnier & Co:
Eric Le Berrigaud & Jean-Jacques Le Fur- Contact Eric Le Berrigaud
- Contact Jean-Jacques Le Fur
- Bryan, Garnier & Co analyst report executive summary